A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal nanoparticle-formulated and conventional anticancer irinotecan

Key Points

• Adverse events related to irinotecan show distinct patterns between formulations and delivery methods, impacting treatment considerations.
• Significant differences were observed, including a notable report of 348 adverse events for conventional irinotecan versus 150 for liposomal nanoparticles.
• Assessment using the FDA Adverse Event Reporting System provides comprehensive insights into real-world drug safety outcomes across various oncology settings.
• Findings highlight the potential importance of formulation type on the safety and efficacy of anticancer therapies, warranting further investigation.